Infinity Pharmaceuticals, Inc. Stock price
Equities
INFI.Q
US45665G3039
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | -99.00% | -99.96% |
Mar. 25 | North American Morning Briefing : Tech in Focus on -2- | DJ |
Mar. 07 | Revised Liquidation Plan Approved for Infinity Pharmaceuticals, Inc. | CI |
Financials (USD)
Sales 2021 | 1.86M | Sales 2022 | 2.59M | Capitalization | 49.59M |
---|---|---|---|---|---|
Net income 2021 | -45M | Net income 2022 | -44M | EV / Sales 2021 | 91.8 x |
Net cash position 2021 | 29.67M | Net Debt 2022 | 11.04M | EV / Sales 2022 | 23.4 x |
P/E ratio 2021 |
-4.25
x | P/E ratio 2022 |
-1.11
x | Employees | 30 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 97.27% |
1 week | -99.00% | ||
3 months | -99.95% | ||
6 months | -99.99% | ||
Current year | -99.96% |
Managers | Title | Age | Since |
---|---|---|---|
Seth Tasker
CEO | Chief Executive Officer | 45 | 08-02-29 |
Jennifer Roberts
PRN | Corporate Officer/Principal | - | 17-09-30 |
Melissa Hackel
PRN | Corporate Officer/Principal | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Anthony Evnin
BRD | Director/Board Member | 83 | 06-08-31 |
Norman Selby
BRD | Director/Board Member | 71 | 12-03-11 |
David W. Beier
BRD | Director/Board Member | 75 | 18-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 0.000001 | 0.00% | 3,000 |
24-03-25 | 0.000001 | 0.00% | 3,194 |
24-03-22 | 0.000001 | -99.00% | 2,748 |
24-03-20 | 0.0001 | +900.00% | 680 |
End-of-day quote OTC Markets, March 26, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
-99.96% | 90 | |
+9.30% | 46.03B | |
+52.73% | 44.55B | |
+7.15% | 40.8B | |
-8.78% | 28.25B | |
+18.68% | 27.71B | |
-21.92% | 18.82B | |
+14.62% | 13.91B | |
+31.85% | 12.43B | |
+4.47% | 10.81B |